|
注册号: Registration number: |
ChiCTR2100050494 |
|
最近更新日期: Date of Last Refreshed on: |
2022-05-02 17:20:10 |
|
注册时间: Date of Registration: |
2021-08-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
维持创新表达认知干预对轻度认知障碍患者的效果评价 |
|
Public title: |
The effects of maintenance creative expression program to mild cognitive impairment of the elderly |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
维持创新表达认知干预对轻度认知障碍患者的效果评价 |
|
Scientific title: |
The effects of maintenance creative expression program to mild cognitive impairment of the elderly |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
骆钰婷 |
研究负责人: |
李红 |
|
Applicant: |
Luo Yuting |
Study leader: |
Li Hong |
|
申请注册联系人电话: Applicant telephone: |
+86 15750866033 |
研究负责人电话:
Study leader's |
+86 13705070219 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
599317498@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
leehong99@126.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
福建省福州市闽侯县上街镇学园路1号福建医科大学护理学院 |
研究负责人通讯地址: |
福建省福州市鼓楼区东街134号 |
|
Applicant address: |
1 Xueyuan Road, Shangjie Town, Minhou County, Fuzhou, Fujian |
Study leader's address: |
134 Dong Street, Gulou District, Fuzhou, Fujian |
|
申请注册联系人邮政编码: Applicant postcode: |
350122 |
研究负责人邮政编码: Study leader's postcode: |
|
|
申请人所在单位: |
福建医科大学 |
||
|
Applicant's institution: |
Fujian Medical University |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
K2021-05-024 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
福建省立医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Fujian Provincial Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-05-27 00:00:00 | ||
|
伦理委员会联系人: |
郑富豪 |
||
|
Contact Name of the ethic committee: |
Zheng Fuhao |
||
|
伦理委员会联系地址: |
福建省福州市鼓楼区东街134号福建省立医院科研处 |
||
|
Contact Address of the ethic committee: |
134 Dong Street, Gulou District, Fuzhou, Fujian |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
福建医科大学 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor: |
Fujian Medical University |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
福建省福州市台江区交通路88号 |
||||||||||||||||||||||||||||||||||||||||||||
|
Primary sponsor's address: |
88 Jiaotong Road, Taijiang District, Fuzhou, Fujian |
||||||||||||||||||||||||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
经费或物资来源: |
国家自然科学基金(82071222) |
||||||||||||||||||||||||||||||||||||||||||||
|
Source(s) of funding: |
National Nature Science Foundation of China (82071222) |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病: |
轻度认知障碍 |
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease: |
mild cognitive impairment (MCI) |
||||||||||||||||||||||||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||||||||||||||||||||||||
|
研究目的: |
1.构建适用于MCI患者的维持创新表达认知干预方案; 2.评价维持创新表达认知干预对MCI患者的干预效果。 |
||||||||||||||||||||||||||||||||||||||||||||
|
Objectives of Study: |
1. Construct a cognitive intervention program for maintaining innovative expression for MCI patients; 2. To evaluate the effect of maintaining innovative expression cognitive intervention on MCI patients. |
||||||||||||||||||||||||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||||||||||||||||||||||||
|
排除标准: |
1. 神经系统疾病或者其他严重的慢性病; |
||||||||||||||||||||||||||||||||||||||||||||
|
Exclusion criteria: |
1. Nervous system diseases or other serious chronic diseases; |
||||||||||||||||||||||||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-09-01 00:00:00至 To 2022-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2021-09-01 00:00:00 至 To 2021-10-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
正在进行 Recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
在进行随机分组之前,不涉及受试者募集和数据收集的研究人员将使用随机数字网站( http://www.randomizer.org/)生成一个随机数字表。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Before randomisation, a researcher not involved in subject recruitment and data collection will prepare a randomisation list with 37 sets of numbers, where 1, 2, and 3 represent the CrEAS, active control, and waitlist control groups, respectively, using Research Randomizer software (http://www.randomizer.org/). |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
本研究属于非药物干预试验,无法对干预者和参与者设盲,因此本研究仅对数据收集者和统计人员设盲 |
|
Blinding: |
Due to the nature of non-pharmacological interventions, the data collector and statisticians but not the participants and intervention staff will be blinded. |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究完成后,相关数据将以URL或DOI的形式提供 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Research data and research-related materials will be available in a repository or online. After completion of the study, relevant data will be provided in the form of a URL or DOI. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究将使用电子数据采集(EDC)系统,研究中心的所有临床试验数据均将以电子格式录入eCRF。数据的采集,包括录入、纠正和更改均由研究者本人或研究者指定的研究中心授权工作人员进行。监查员不能录入数据到eCRF。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This study will use an electronic data collection (EDC) system, and all clinical trial data of the research center will be entered into eCRF in electronic format. Data collection, including entry, correction, and modification are performed by the investigator or the authorized staff of the research center designated by the investigator. Auditors cannot enter data into eCRF. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |